Brief: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
16/05/2025 21:31
May 16 (Reuters) - Summit Therapeutics Inc SMMT.O: SUMMIT THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text: ID:nBwcbzZZva Further company coverage: SMMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)